OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders like type 2 diabetes, NASH (nonalcoholic steatohepatitis), and severe dyslipidemias, raised $67 million in Series B funding.
The funding round was co-led by Ascenta Capital and Woodline Partners, with additional investment from Samsara Biocapital, Longitude Capital, Enavate Sciences, NuevaBio, and Eli Lilly and Company.
OrsoBio intends to use the fresh funds to accelerate the development of its mitochondrial protonophore-based therapies, which are designed to address the underlying metabolic drivers of obesity and associated conditions.
The company is advancing a pipeline of innovative therapies targeting core pathways in energy metabolism, with four programs in various stages of clinical and preclinical development.
Their portfolio includes several promising compounds, including:
- TLC-6740: A liver-targeted mitochondrial protonophore being tested in a 12-week Phase 1b trial for obesity.
- TLC-1180: A long-acting mitochondrial protonophore designed for weekly oral or subcutaneous dosing.
- TLC-1235: A controlled-release mitochondrial protonophore with demonstrated metabolic benefits across various studies.
- TLC-3595: An ACC2 inhibitor in a Phase 2a trial for type 2 diabetes.
- TLC-2716: An LXR inverse agonist in a Phase 2a trial for severe hypertriglyceridemia and NASH.
According to the official press statement, the new funding will also enable OrsoBio to advance its clinical trials and expand the potential impact of its innovative treatments for patients living with obesity and its associated disorders.